Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Purpose: HSP90, a highly conserved molecular chaperone that regulates the function of several oncogenic client proteins, is altered in glioblastoma. However, HSP90 inhibitors currently in clinical trials are short-acting, have unacceptable toxicities, or are unable to cross the blood–brain barrier (BBB). We examined the efficacy of onalespib, a potent, long-acting novel HSP90 inhibitor as a single agent and in combination with temozolomide (TMZ) against gliomas in vitro and in vivo. Experimental Design: The effect of onalespib on HSP90, its client proteins, and on the biology of glioma cell lines and patient-derived glioma-initiating cells (GSC) was determined. Brain and plasma pharmacokinetics of onalespib and its ability to inhibit HSP90 in vivo were assessed in non–tumor-bearing mice. Its efficacy as a single agent or in combination with TMZ was assessed in vitro and in vivo using zebrafish and patient-derived GSC xenograft mouse glioma models. Results: Onalespib-mediated HSP90 inhibition depleted several survival-promoting client proteins such as EGFR, EGFRvIII, and AKT, disrupted their downstream signaling, and decreased the proliferation, migration, angiogenesis, and survival of glioma cell lines and GSCs. Onalespib effectively crossed the BBB to inhibit HSP90 in vivo and extended survival as a single agent in zebrafish xenografts and in combination with TMZ in both zebrafish and GSC mouse xenografts. Conclusions: Our results demonstrate the long-acting effects of onalespib against gliomas in vitro and in vivo, which combined with its ability to cross the BBB support its development as a potential therapeutic agent in combination with TMZ against gliomas. Clin Cancer Res; 23(20); 6215–26. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 1×
“S3A) and determined the CI of the treatments (43); the combination of onalespib and TMZ was synergistic in the U251 and LN229 cells with a CI of 0.”
BackgroundSingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063 · cited 1×
“Significantly, both inter- and intratumoral driver events converge on a few key pathways involving EGFR, AKT, and ERK, indicating that these pathways are central to tumorigenesis in GBM (6, 7).”
BackgroundThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502 · cited 1×
“HSP90 is expressed in the cytoplasm of glioma xenograft cells HSP90 is known to be overexpressed in several solid and hematologic malignancies (10).”
BackgroundHsp90 as a capacitor for morphological evolution
Rutherford, S. L., & Lindquist, S. (1998) · Nature · doi:10.1038/24550 · Cited by 2,270 · cited 1×
“Tumor cells respond to chemotherapy, radiotherapy, or targeted therapy by adaptively activating DNA repair pathways and by oncogenic reprograming that switches tumor dependence to alternative kinase pathways, by a process facilitated by HSP90 (13, 14).”
BackgroundQuantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition
Taipale, M., Krykbaeva, I., Koeva, M., Kayatekin, C., Westover, K. D., Karras, G. I., & Lindquist, S. (2012) · Cell · doi:10.1016/j.cell.2012.06.047 · Cited by 879
Cited by
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials
Patton, E. E., Zon, L. I., & Langenau, D. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00210-8 · Cited by 567
Wang, H., Deng, G., Ai, M., Xu, Z., Mou, T., Yu, J., Liu, H., Wang, S., & Li, G. (2019) · Oncogene · doi:10.1038/s41388-018-0532-5 · Cited by 117
Yang, H., Liang, S.-Q., Xu, D., Yang, Z., Marti, T. M., Gao, Y., Kocher, G. J., Zhao, H., Schmid, R. A., & Peng, R.-W. (2019) · Oncogenesis · doi:10.1038/s41389-019-0158-7 · Cited by 58
Zhang, H., Yin, X., Zhang, X., Zhou, M., Xu, W., Wei, Z., Song, C., Han, S., & Han, W. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221118202 · Cited by 40
Marcyk, P. T., LeBlanc, E. V., Kuntz, D. A., Xue, A., Ortiz, F., Trilles, R., Bengtson, S., Kenney, T. M. G., Huang, D. S., Robbins, N., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01777 · Cited by 40
Metadata
- Authors
- Canella, A., Welker, A. M., Yoo, J. Y., Xu, J., Abas, F. S., Kesanakurti, D., Nagarajan, P., Beattie, C. E., Sulman, E. P., Liu, J., Gumin, J., Lang, F. F., Gurcan, M. N., Kaur, B., Sampath, D., & Puduvalli, V. K.
- Venue
- Clinical Cancer Research
- Published
- 2017-10-12
- Volume
- 23
- Issue
- 20
- Pages
- 6215-6226
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2732060616
- Cited by
- 67
- References
- 7
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-3151
- The paper
- Canella, A., Welker, A. M., Yoo, J. Y., Xu, J., Abas, F. S., Kesanakurti, D., Nagarajan, P., Beattie, C. E., Sulman, E. P., Liu, J., Gumin, J., Lang, F. F., Gurcan, M. N., Kaur, B., Sampath, D., & Puduvalli, V. K. (2017). Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-3151
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.